United Laboratories International Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	13.4yrs

Recent management updates

Recent updates

CEO

United Laboratories International Holdings has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hoi Shan Tsoi	Executive Chairman	15yrs	CN¥4.00m	0.90% CN¥ 18.5m
Wing Hon Leung	Vice Chairman	17.4yrs	CN¥3.98m	0.0012% CN¥ 24.9k
Su Yan Zhu	VP & Executive Director	13.4yrs	CN¥2.43m	0.000010% CN¥ 205.7
Xian Hong Zou	VP & Executive Director	13.4yrs	CN¥2.43m	0.011% CN¥ 226.5k
Siu Chit Choy	Global Director of Intermediate & Bulk Medicine and Executive Director	10.8yrs	CN¥2.66m	0.0065% CN¥ 133.5k
Yu Ping Fang	VP & Executive Director	13.4yrs	CN¥2.47m	no data
Ming Song	Independent Non-Executive Director	16.9yrs	CN¥222.00k	no data
Peng Oon Chong	Independent Non-Executive Director	15.1yrs	CN¥222.00k	no data
Qiushi Fu	Independent Non-Executive Director	less than a year	no data	no data

13.4yrs

Average Tenure

58yo

Average Age

Experienced Board: UNJ's board of directors are seasoned and experienced ( 13.4 years average tenure).

United Laboratories International Holdings Management

Management criteria checks 1/4

Key information

Recent management updates

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥1.49 (vs CN¥0.87 in FY 2022)

Investor sentiment improves as stock rises 19%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.54 in FY 2021)

Now 20% undervalued

Less than half of directors are independent

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.40 in FY 2020)

Less than half of directors are independent

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

The United Laboratories International Holdings Limited Announces Updated Information of the Group's Products

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

The United Laboratories International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: €0.52

New 90-day low: €0.58

New 90-day low: €0.67

New 90-day low: €0.71

First half earnings released

New 90-day high - €0.99

First half earnings released

The United Laboratories International Holdings Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - €0.71

CEO

Board Members

Average Tenure

Average Age